|
1
|
Rossari F, Minutolo F and Orciuolo E:
Past, present, and future of Bcr-Abl inhibitors: From chemical
development to clinical efficacy. J Hematol Oncol. 11:842018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shah NP, Tran C, Lee FY, Chen P, Norris D
and Sawyers CL: Overriding imatinib resistance with a novel ABL
kinase inhibitor. Science. 305:399–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tu MM, Lee FYF, Jones RT, Kimball AK,
Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, et
al: Targeting DDR2 enhances tumor response to anti-PD-1
immunotherapy. Sci Adv. 5:eaav24372019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mestermann K, Giavridis T, Weber J, Rydzek
J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H and Hudecek
M: The tyrosine kinase inhibitor dasatinib acts as a pharmacologic
on/off switch for CAR T cells. Sci Transl Med. 11:eaau59072019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu Y, Tchkonia T, Pirtskhalava T, Gower
AC, Ding H, Giorgadze N, Palmer AK, Ikeno Y, Hubbard GB, Lenburg M,
et al: The Achilles' heel of senescent cells: From transcriptome to
senolytic drugs. Aging Cell. 14:644–658. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kirkland JL, Tchkonia T, Zhu Y,
Niedernhofer LJ and Robbins PD: The clinical potential of senolytic
drugs. J Am Geriatr Soc. 65:2297–2301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Von Massenhausen A, Sanders C, Bragelmann
J, Konantz M, Queisser A, Vogel W, Kristiansen G, Duensing S,
Schrock A, Bootz F, et al: Targeting DDR2 in head and neck squamous
cell carcinoma with dasatinib. Int J Cancer. 139:2359–2369. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Das J, Chen P, Norris D, Padmanabha R, Lin
J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, et al:
2-aminothiazole as a novel kinase inhibitor template.
Structure-activity relationship studies toward the discovery of
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)
−1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-
carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase
inhibitor. J Med Chem. 49:6819–6832. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Johnson FM, Saigal B, Tran H and Donato
NJ: Abrogation of signal transducer and activator of transcription
3 reactivation after Src kinase inhibition results in synergistic
antitumor effects. Clin Cancer Res. 13:4233–4244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang X, Wang J, Dai J, Shao J, Ma J, Chen
C, Ma S, He Q, Luo P and Yang B: Autophagy protects against
dasatinib-induced hepatotoxicity via p38 signaling. Oncotarget.
6:6203–6217. 2015.PubMed/NCBI
|
|
11
|
Xu Z, Jin Y, Yan H, Gao Z, Xu B, Yang B,
He Q, Shi Q and Luo P: High-mobility group box 1 protein-mediated
necroptosis contributes to dasatinib-induced cardiotoxicity.
Toxicol Lett. 296:39–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi J, Gao W and Shao F: Pyroptosis:
Gasdermin-mediated programmed necrotic cell death. Trends Biochem
Sci. 42:245–254. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Gao W, Shi X, Ding J, Liu W, He H,
Wang K and Shao F: Chemotherapy drugs induce pyroptosis through
caspase-3 cleavage of a gasdermin. Nature. 547:99–103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rogers C, Fernandes-Alnemri T, Mayes L,
Alnemri D, Cingolani G and Alnemri ES: Cleavage of DFNA5 by
caspase-3 during apoptosis mediates progression to secondary
necrotic/pyroptotic cell death. Nat Commun. 8:141282017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Masuda Y, Futamura M, Kamino H, Nakamura
Y, Kitamura N, Ohnishi S, Miyamoto Y, Ichikawa H, Ohta T, Ohki M,
et al: The potential role of DFNA5, a hearing impairment gene, in
p53-mediated cellular response to DNA damage. J Hum Genet.
51:652–664. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu H, Zhang S, Wu J, Chen M, Cai MC, Fu Y,
Li W, Wang J, Zhao X, Yu Z, et al: Molecular targeted therapies
elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor
cell death. Clin Cancer Res. 24:6066–6077. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Yin B, Li D, Wang G, Han X and Sun
X: GSDME mediates caspase-3-dependent pyroptosis in gastric cancer.
Biochem Biophys Res Commun. 495:1418–1425. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Watanabe S, Yoshida T, Kawakami H,
Takegawa N, Tanizaki J, Hayashi H, Takeda M, Yonesaka K, Tsurutani
J and Nakagawa K: T790M-selective EGFR-TKI combined with dasatinib
as an optimal strategy for overcoming EGFR-TKI resistance in
T790M-positive non-small cell lung cancer. Mol Cancer Ther.
16:2563–2571. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao J, Qiu X, Xi G, Liu H, Zhang F, Lv T
and Song Y: Downregulation of GSDMD attenuates tumor proliferation
via the intrinsic mitochondrial apoptotic pathway and inhibition of
EGFR/Akt signaling and predicts a good prognosis in non-small cell
lung cancer. Oncol Rep. 40:1971–1984. 2018.PubMed/NCBI
|
|
20
|
Wang L, Li K, Lin X, Yao Z, Wang S, Xiong
X, Ning Z, Wang J, Xu X, Jiang Y, et al: Metformin induces human
esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1
axis. Cancer Lett. 450:22–31. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsuchiya K, Nakajima S, Hosojima S, Thi
Nguyen D, Hattori T, Manh Le T, Hori O, Mahib MR, Yamaguchi Y,
Miura M, et al: Caspase-1 initiates apoptosis in the absence of
gasdermin D. Nat Commun. 10:20912019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fritsch M, Günther SD, Schwarzer R, Albert
MC, Schorn F, Werthenbach JP, Schiffmann LM, Stair N, Stocks H,
Seeger JM, et al: Caspase-8 is the molecular switch for apoptosis,
necroptosis and pyroptosis. Nature. 575:683–687. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
El-Deiry WS: The role of p53 in
chemosensitivity and radiosensitivity. Oncogene. 22:7486–7495.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Webb MS, Miller AL and Thompson EB: In CEM
cells the autosomal deafness gene dfna5 is regulated by
glucocorticoids and forskolin. J Steroid Biochem Mol Biol.
107:15–21. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang CJ, Tang L, Shen DW, Wang C, Yuan QY,
Gao W, Wang YK, Xu RH and Zhang H: The expression and regulation of
DFNA5 in human hepatocellular carcinoma DFNA5 in hepatocellular
carcinoma. Mol Biol Rep. 40:6525–6531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Homma S, Ishii Y, Morishima Y, Yamadori T,
Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N,
et al: Nrf2 enhances cell proliferation and resistance to
anticancer drugs in human lung cancer. Clin Cancer Res.
15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang HX, Chen Y, Xu R and He QY: Nrf2
mediates the resistance of human A549 and HepG2 cancer cells to
boningmycin, a new antitumor antibiotic, in vitro through
regulation of glutathione levels. Acta Pharmacol Sin. 39:1661–1669.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sen B, Peng S, Tang X, Erickson HS,
Galindo H, Mazumdar T, Stewart DJ, Wistuba I and Johnson FM:
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to
dasatinib. Sci Transl Med. 4:136ra702012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang CC, Li CG, Wang YF, Xu LH, He XH,
Zeng QZ, Zeng CY, Mai FY, Hu B and Ouyang DY: Chemotherapeutic
paclitaxel and cisplatin differentially induce pyroptosis in A549
lung cancer cells via caspase-3/GSDME activation. Apoptosis.
24:312–325. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tièche CC, Gao Y, Bührer ED, Hobi N,
Berezowska SA, Wyler K, Froment L, Weis S, Peng RW, Bruggmann R, et
al: Tumor initiation capacity and therapy resistance are
differential features of EMT-related subpopulations in the NSCLC
cell line A549. Neoplasia. 21:185–196. 2019. View Article : Google Scholar : PubMed/NCBI
|
